Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating
Baird Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $260
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $225 to $300
Maintaining Hold on Biogen Amid Uncertain Efficacy and Competitive SLE Market
Needham Reiterates Buy on Biogen, Maintains $285 Price Target
Buy Rating Affirmed for Biogen on Promising Phase 3 Results and Strategic Development Plans for Lupus Drug Dapi
Update: Wedbush Cuts Biogen's Price Target to $205 From $210 Due to Lack of 'Clear-Cut Revenue Driver', Keeps Neutral Rating
Biogen Is Maintained at Neutral by Wedbush
Biogen Analyst Ratings
Wedbush Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $205
Wedbush Trims Price Target on Biogen to $205 From $210, Keeps Neutral Rating
Biogen Price Target Maintained With a $292.00/Share by RBC Capital
Biogen Analyst Ratings
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $292
RBC Capital Keeps Their Buy Rating on Biogen (BIIB)
Cantor Fitzgerald Reiterates Overweight on Biogen, Maintains $292 Price Target
Biogen Analyst Ratings
BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $260
Optimistic Buy Rating for Biogen on Strategic Cost-Cutting and Growth Asset Prioritization